BriaCell Therapeutics Corp. (BCTX) stock
BCTXNasdaqPharmaceutical PreparationsFiscal year ends July 31Also trades as BCTXL, BCTXZ
$3.51+0.21 (+6.36%)
Close on Nov 17, 2026Market cap $30.65MP/E –Yield –
BriaCell Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
BriaCell Therapeutics's operating income for the twelve months ending Jul 31, 2026 was -$36.05M. For fiscal 2026 it was -$36.05M. The highest annual figure on record is -$3.94M in fiscal 2020.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Jul 31, 2026 | -$36.05M | – |
| FY2025 | Jul 31, 2025 | -$27.20M | – |
| FY2024 | Jul 31, 2024 | -$33.33M | – |
| FY2023 | Jul 31, 2023 | -$23.27M | – |
| FY2022 | Jul 31, 2022 | -$15.29M | – |
| FY2021 | Jul 31, 2021 | -$6.98M | – |
| FY2020 | Jul 31, 2020 | -$3.94M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2026CQ2 2026 | Jul 31, 2026 | -$12.58M | – |
| Q3 FY2026CQ1 2026 | Apr 30, 2026 | -$7.62M | – |
| Q2 FY2026CQ4 2025 | Jan 31, 2026 | -$7.53M | – |
| Q1 FY2026CQ3 2025 | Oct 31, 2025 | -$8.32M | – |
| Q4 FY2025CQ2 2025 | Jul 31, 2025 | -$8.55M | – |
| Q3 FY2025CQ1 2025 | Apr 30, 2025 | -$6.33M | – |
| Q2 FY2025CQ4 2024 | Jan 31, 2025 | -$7.17M | – |
| Q1 FY2025CQ3 2024 | Oct 31, 2024 | -$5.15M | – |
| Q4 FY2024CQ2 2024 | Jul 31, 2024 | -$5.77M | – |
| Q3 FY2024CQ1 2024 | Apr 30, 2024 | -$9.23M | – |
| Q2 FY2024CQ4 2023 | Jan 31, 2024 | -$9.83M | – |
| Q1 FY2024CQ3 2023 | Oct 31, 2023 | -$8.50M | – |
| Q4 FY2023CQ2 2023 | Jul 31, 2023 | -$7.71M | – |
| Q3 FY2023CQ1 2023 | Apr 30, 2023 | -$5.68M | – |
| Q2 FY2023CQ4 2022 | Jan 31, 2023 | -$4.49M | – |
| Q1 FY2023CQ3 2022 | Oct 31, 2022 | -$5.40M | – |
| Q4 FY2022CQ2 2022 | Jul 31, 2022 | -$5.23M | – |
| Q3 FY2022CQ1 2022 | Apr 30, 2022 | -$4.12M | – |
| Q2 FY2022CQ4 2021 | Jan 31, 2022 | -$3.65M | – |
| Q1 FY2022CQ3 2021 | Oct 31, 2021 | -$2.28M | – |
| Q4 FY2021CQ2 2021 | Jul 31, 2021 | -$1.60M | – |
| Q3 FY2021CQ1 2021 | Apr 30, 2021 | -$4.81M | – |
| Q2 FY2021CQ4 2020 | Jan 31, 2021 | -$190.15K | – |
See a number that looks wrong?